StockData
City Therapeutics, Inc. logo

City Therapeutics, Inc. (CTY) shareholders

CTYNasdaqPharmaceutical PreparationsFiscal year ends December 31
$17.50+0.52 (+3.06%)

Close on Nov 17, 2026Market cap –P/E –Yield –

Ownership

Who owns City Therapeutics's shares

Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
2 buys · 0 sales
Net bought $6.12M

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Kristina Burow
Joint filing with ARCH Venture Fund XII, L.P. (25.60%), ARCH Venture Partners XII, L.P. (25.60%) and 4 more
13,692,50725.60%13D (active)Oct 19, 2026
Abigail P. Johnson
Joint filing with FMR LLC (14.00%)
7,025,54314.00%13G (passive)Oct 30, 2026
Raymond Debbane
Joint filing with Invus Public Equities, L.P. (8.10%), Invus Public Equities Advisors, LLC (8.10%) and 2 more
4,342,8668.10%13G (passive)Oct 16, 2026
Halvorsen Ole Andreas
Joint filing with Viking Global Investors LP (7.00%), Viking Global Opportunities Parent GP LLC (7.00%) and 1 more
3,727,0057.00%13G (passive)Oct 19, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares ownedLatest filing
Andrew C. OrthPresident & CEO, Director1,063,154Oct 19, 2026
Tracy ZimmermannChief Scientific Officer–Oct 15, 2026
Keith RegnanteChief Financial Officer–Oct 15, 2026
Baisong MeiChief Medical Officer228,743Oct 15, 2026
Sebastian TrousilChief Operating Officer534,511Oct 15, 2026
Barry E. GreeneDirector–Oct 19, 2026
John MaraganoreDirector2,107,706Oct 19, 2026
Sara NochurDirector–Oct 19, 2026
Robert NelsenDirector, 10% owner13,692,507Oct 19, 2026
Ron M. PhilipDirector–Oct 19, 2026
Keith Crandell10% owner–Oct 19, 2026
Kristina Burow10% owner–Oct 19, 2026
Steven Gillis10% owner–Oct 19, 2026
ARCH Venture Fund XII, L.P.10% owner–Oct 19, 2026
ARCH Venture Partners XII, L.P.10% owner–Oct 19, 2026
ARCH Venture Partners XII, LLC10% owner13,692,507Oct 19, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
ARCH Venture Partners XII, LLC
10% owner
Oct 19, 2026Buy+170,000$18.00$3.06M13,692,507
ARCH Venture Partners XII, LLC
10% owner
Oct 19, 2026Conversion+2,027,006––13,522,507
ARCH Venture Partners XII, LLC
10% owner
Oct 19, 2026Conversion+5,482,309––11,495,501
ARCH Venture Partners XII, LLC
10% owner
Oct 19, 2026Conversion+3,294,900––6,013,192
Robert Nelsen
Director, 10% owner
Oct 19, 2026Buy+170,000$18.00$3.06M13,692,507
Robert Nelsen
Director, 10% owner
Oct 19, 2026Conversion+2,027,006––13,522,507
Robert Nelsen
Director, 10% owner
Oct 19, 2026Conversion+5,482,309––11,495,501
Robert Nelsen
Director, 10% owner
Oct 19, 2026Conversion+3,294,900––6,013,192
John Maraganore
Director
Oct 19, 2026Conversion+610,759––1,470,692

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
1M shares short
Days to cover
2.3
At 0M shares a day
Change since last report
–
Short volume, 20 days
74.8%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of City Therapeutics's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.

Congress trades

1 trade in City Therapeutics reported by 1 member of the House

MemberTypeTradedAmountFiled
Raúl M. Grijalva
AZ03
SoldJan 15, 2014$1K–15KFeb 5, 2014

See a number that looks wrong?